Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US

2Firsts Events by 2FIRSTS, edited by Sophia Lv
Aug.19.2024
Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Accorto CEO Tom Beaudet and CSO Dr. Vince Angelico visit 2FIRSTS HQ for in-depth discussion on US e-cigarette industry.

On August 19, Tom Beaudet, CEO of the U.S. compliance company Accorto, and Dr. Vince Angelico, CSO (Chief Scientific Officer), visited the headquarters of 2FIRSTS to have a detailed discussion with Alan Zhao, co-founder and CEO of 2FIRSTS. Both sides explored the high-quality development of the e-cigarette industry in the American market.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Tom (third from the right), Vincent (fourth from the right), Alan Zhao (second from the right), and 2FIRSTS staff members posing for a photo. | Image source: 2FIRSTS

 

During the meeting, Alan Zhao warmly welcomed the arrival of the Accorto delegation and expressed appreciation for their professional insights in the field of PMTA compliance. Alan Zhao stated that with the U.S. Food and Drug Administration (FDA) continuously strengthening its regulation and enforcement of the e-cigarette market, compliance in the e-cigarette industry has become a crucial issue that companies cannot afford to overlook. In the face of market changes, companies must pay close attention to compliance services in order to ensure their sustainable and steady development.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
2024 Global New Tobacco Regulations Report" produced by 2FIRSTS|Image source: 2FIRSTS

 

In order to deepen mutual understanding and cooperation, Alan Zhao on behalf of 2FIRSTS presented Tom with the "2024 Global New Tobacco Regulation Report" (English version) produced by 2FIRSTS. The report provides a comprehensive analysis of the current global regulation of novel tobacco products and their development trends, offering valuable insights and guidance to the industry.

 

Tom highly praised 2FIRSTS' professionalism and contribution to the industry's development, and stated that he looks forward to deeper collaboration with 2FIRSTS in the e-cigarette compliance field in the future. Accorto, as a leading provider of PMTA compliance services, has been dedicated to assisting e-cigarette companies in FDA reviews to ensure products can legally enter the US market.

 

This exchange not only deepened mutual understanding between both parties, but also laid a solid foundation for future cooperation. 2FIRSTS and Accorto have both expressed their commitment to working together to promote the healthy and orderly development of the e-cigarette industry, providing global consumers with safer and more compliant e-cigarette products.

 

As a key media and research institution in the e-cigarette industry, 2FIRSTS will continue to leverage its influence within the industry to promote information exchange and knowledge sharing. We will work with partners like Accorto to contribute to the high-quality development of the e-cigarette industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT Adds Former Apple General Counsel Bruce Sewell to Board as Finance, Legal, Marketing and Regional Leadership Shift
BAT Adds Former Apple General Counsel Bruce Sewell to Board as Finance, Legal, Marketing and Regional Leadership Shift
British American Tobacco has appointed former Apple Senior Vice President, General Counsel and Secretary Bruce Sewell as an independent non-executive director, effective January 1, 2027. He will also join BAT's Audit and Nominations Committees. BAT Chair Luc Jobin highlighted Sewell's experience in technology, government and regulatory affairs, public-company governance and AI-company boards. Over the past 18 months, BAT has changed or announced changes to its CFO, general counsel, CMO and APMEA regional leadership, while the main board has also seen multiple changes. The appointment comes as BAT advances Horizon 2030 and its Fit2Win transformation while expanding New Categories and reshaping parts of its digital, technology and operating structure.
Business
Oct.29
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11
North Carolina Tightens Vape Product Directory Enforcement, Expands State and Local Powers as Violators Face Fines, Product Seizures and License Suspension or Revocation
North Carolina Tightens Vape Product Directory Enforcement, Expands State and Local Powers as Violators Face Fines, Product Seizures and License Suspension or Revocation
North Carolina has expanded enforcement of its vapor product directory rules, authorizing more state and local law enforcement participation and establishing a task force led by the State Bureau of Investigation. The legislation requires at least one unannounced compliance inspection annually for retailers, distributors and wholesalers handling covered products. Penalties effective October 1, 2026, include civil fines of $500–$750 for a first violation and $1,000–$1,500 for repeated violations within 12 months, along with potential license suspension or revocation. Manufacturers may face penalties of $10,000 per unlisted product. The measures strengthen the product directory system established in 2024.
Regulations
Oct.28
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives